Oxford Immunotec: Oxford Immunotec to Present at the Baird 2016 Global Healthcare Conference

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Rick Altieri, Chief Financial Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016, at 2:35 p.m. ET at the New York Palace in New York, NY.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions.  The Company's first product is the T-SPOT^®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market.  In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com (http://www.oxfordimmunotec.com/).

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media Inquiries: 
Caroline Crawley 
Oxford Immunotec
Tel: [phone]
[e-mail] (mailto:[e-mail])

For Investor Inquiries: 
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: [phone]
[e-mail] (mailto:[e-mail])

Mark Klausner
Westwicke Partners
Tel: [phone]
[e-mail] (mailto:[e-mail])

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

HUG#2037145